THE EVALUATION OF THE EFFECTIVENESS AND SAFETY OF THE USE OF FIXED TRIPLE ORAL SUGAR-REDUCING THERAPY WITH DEBISTAL-GM IN PATIENTS WITH TYPE 2 DIABETES WITH OBESITY

Given the complexity and versatility of the pathogenesis of type 2 diabetes choice of antihyperglycemic drugs is based on the importance of a simultaneous combined effect on several links in the pathogenesis of type 2 diabetes. The aim of the study was to study the hypoglycemic efficacy, clinical tolerance and safety of Debistal-GM in obese patients with type 2 diabetes. As a result of the study, high clinical efficacy, good tolerability and safety of Debistal-GM in obese type 2 diabetes were established. Inclusion criteria for the use of Debistal-GM are patients with type 2 diabetes with glycated hemoglobin values above 9%, but below 11%; with a diabetes duration of more than 5 years, with a body mass index of more than 30 kg / m 2 .